Private practice with Dr Seth Bilazarian

View all posts »

DES or bare-metal stents in STEMI patients?

Apr 20, 2010 09:30 EDT


Randomized clinical trials do not seem to have contributed to a definite answer regarding the selection of drug-eluting or bare-metal stent for acute MI. What is your rationale when making your decision?

See:

DES in AMI: Benefits maintained at three years in SESAMI

Two-year Massachusetts registry results support mortality benefit of DES in AMI

DES in AMI: Some reassurances, more questions from TYPHOON and STRATEGY

HORIZONS AMI: Drug-eluting stent safe and effective in the setting of STEMI

 

 








Your comments
DES or bare-metal stents in STEMI patients?
# 1 of 1
April 25, 2010 12:09 (EDT)
alndot

 

I am 83 years old. 14 years ago I had a blockage drilled out in my left descending artery. I had one followup with the surgeon. For the past 14 years the only treatment I have received is Chelation. I know of dozens of others who are alive because of Chelation.

I followed the NIH Chelation study with interest wondering when and how it would be stopped because of the tremendous amount of money at stake for the Heart Industry.

It is sad when money and not health is the motivation for unneeded surgery.


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.

Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.

Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:

  • Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
  • Practice approaches to the extra clinical issues in dealing with managed care insurers
  • Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
  • Experiences with restrictions on testing and imaging
The video blog (VLOG) will provide an opportunity to share broadly different approaches to the common conundrums we face in caring for patients. My hope is that this forum will provide useful data points for practice outside of tertiary and academic centers and a look inside community hospitals and physician?s practice patterns in the office, starting with mine.